Apellis Pharmaceuticals (APLS) Debt to Equity: 2024-2025
Historic Debt to Equity for Apellis Pharmaceuticals (APLS) over the last 2 years, with Sep 2025 value amounting to $1.13.
- Apellis Pharmaceuticals' Debt to Equity fell 25.14% to $1.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.13, marking a year-over-year decrease of 25.14%. This contributed to the annual value of $1.57 for FY2024, which is N/A change from last year.
- Apellis Pharmaceuticals' Debt to Equity amounted to $1.13 in Q3 2025, which was down 50.86% from $2.31 recorded in Q2 2025.
- In the past 5 years, Apellis Pharmaceuticals' Debt to Equity registered a high of $2.31 during Q2 2025, and its lowest value of $1.13 during Q3 2025.
- In the last 2 years, Apellis Pharmaceuticals' Debt to Equity had a median value of $1.54 in 2024 and averaged $1.68.
- Over the last 5 years, Apellis Pharmaceuticals' Debt to Equity had its largest YoY gain of 67.49% in 2025, and its largest YoY loss of 25.14% in 2025.
- Over the past 2 years, Apellis Pharmaceuticals' Debt to Equity (Quarterly) stood at $1.57 in 2024, then fell by 25.14% to $1.13 in 2025.
- Its last three reported values are $1.13 in Q3 2025, $2.31 for Q2 2025, and $2.19 during Q1 2025.